India to mandate annual audit of pharma suppliers by drugmakers
Source: Reuters
India will make it mandatory for drugmakers to audit their raw material suppliers at least once a year. The government is looking forward to tightening rules after India-made cough syrups were linked to 141 children’s deaths worldwide.
India is trying to reassure buyers about the safety of its $42 billion pharmaceuticals industry, one of the world’s largest. The government made it clear in new mandate, along with additional testing rules for cough syrup exports implemented in June.
WHO linked deaths of 70 children in Gambia, 65 in Uzbekistan and at least 6 in Cameroon last year with contaminated India-made cough syrups.
India’s federal drug regulator, the Central Drugs Standard Control Organisation (CDSCO), conveyed the decision on mandatory audits for raw material and packaging material suppliers in a meeting with industry representatives on Sept. 15, according to a presentation seen by Reuters.
Drugmakers will have to do an audit of their raw materials and packaging suppliers “at least once a year”, the presentation said. Currently, such audits are done occasionally after events, such as a product recall, it said.
India’s Health Ministry did not immediately respond to a request for comment.
Some Indian drugmakers were buying key ingredients from suppliers who did not have a license to sell pharmaceutical-grade products, Reuters has reported. The drugmakers have denied allegations that their products were responsible for deaths.
Drugmakers will also have to inform their licensing authorities, generally, the drug regulator of the state where they are based, of all product recalls, the document showed.
Health experts have previously criticized the lack of data on product recalls after some Indian companies were given drug export licenses by their home state, despite previous violations in other states.
The WHO says the death of 12 children in India in late 2019 after consuming contaminated cough syrup may have been the start of a wave of poisoning by India-made medicines.
In all the cases, the syrups were found to contain high levels of the toxin diethylene glycol (DEG), and or a related chemical, ethylene glycol.
Through the new regulatory steps for pharma products, India wants to build “trust and confidence in quality” and reduce “product failure”, among other things, the presentation said.
Separately, the trade ministry has been holding workshops across the country for drugmakers to “review the regulatory perspectives on DEG contamination and discuss the current regulations in place to prevent it”, according to a statement from the ministry-backed trade body, the Pharmaceuticals Export Promotion Council of India (Pharmexcil).
“Maintaining the quality of pharmaceutical products is crucial to guaranteeing the patient’s safety, failing which could have long-term ramifications for the global public’s confidence in Indian medicines,” Pharmexcil said.
“The Indian pharma units, especially the MSME (small companies) sector are facing new challenges under resource-poor settings to meet global as well as domestic healthcare expectations.”
